Show simple item record

dc.contributor.authorLiu, Haiying
dc.contributor.authorZhang, Zhenqing
dc.contributor.authorLinhardt, Robert J.
dc.date2009
dc.date.accessioned2022-06-23T04:01:53Z
dc.date.available2022-06-23T04:01:53Z
dc.date.issued2009-03-09
dc.identifier.citationLessons learned from the contamination of heparin, H. Liu, Z. Zhang, R.J. Linhardt, Natural Product Reports, 26, 313–321, 2009.
dc.identifier.issn14604752
dc.identifier.issn2650568
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5222
dc.identifier.urihttps://doi.org/10.1039/b819896a
dc.descriptionNatural Product Reports, 26, 313–321
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin is unique as one of the oldest drugs currently still in widespread clinical use as an anticoagulant, a natural product, one of the first biopolymeric drugs, and one of the few carbohydrate drugs. Recently, certain batches of heparin have been associated with anaphylactoid-type reactions, some leading to hypotension and death. These reactions were traced to contamination with a semi-synthetic oversulfated chondroitin sulfate (OSCS). This Highlight reviews the heparin contamination crisis, its resolution, and the lessons learned. Pharmaceutical scientists now must consider dozens of natural and synthetic heparinoids as potential heparin contaminants. Effective assays, which can detect both known and unknown contaminants, are required to monitor the quality of heparin. Safer and better-regulated processes are needed for heparin production.
dc.description.sponsorshipNational Heart, Lung, and Blood Institute
dc.languageen_US
dc.language.isoENG
dc.publisherRoyal Society of Chemistry
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofNatural Product Reports
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleLessons learned from the contamination of heparin
dc.typeArticle
dcterms.accessRightsA full text version is available in DSpace@RPI
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.1039/b819896a
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.pages313-321
rpi.description.volume26


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record